259 related articles for article (PubMed ID: 24559090)
1. Safety and efficacy evaluation of albumin-bound paclitaxel.
Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
[TBL] [Abstract][Full Text] [Related]
2. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
3. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.
Adrianzen Herrera D; Ashai N; Perez-Soler R; Cheng H
Expert Opin Pharmacother; 2019 Jan; 20(1):95-102. PubMed ID: 30439289
[TBL] [Abstract][Full Text] [Related]
6. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
7. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Hirsh V
Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
10. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
12. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
13. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
14. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
15. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF
Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702
[TBL] [Abstract][Full Text] [Related]
16. nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update.
Simon GR
Clin Lung Cancer; 2014 Nov; 15(6):391-7. PubMed ID: 25246384
[TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
Montero AJ; Adams B; Diaz-Montero CM; Glück S
Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779
[TBL] [Abstract][Full Text] [Related]
19. Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.
Socinski MA; Govindan R; Spigel D
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 18):1-16. PubMed ID: 23187688
[TBL] [Abstract][Full Text] [Related]
20. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
